InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $11.290 2.7 (31.43%)+
Announcement
Release
13 May 2026 8:30AM
Price at Release
$8.590
Full Release
download
Summary
Anteris Technologies Ltd announced its financial results for the first quarter ended 31 March 2026, highlighting significant progress in its global pivotal trial, the PARADIGM Trial, aimed at evaluating the DurAVR® Transcatheter Heart Valve. The company raised US$320 million to support the trial and advance towards the global commercialization of its DurAVR® THV System. Notable achievements include the commencement of U.S. enrolment and presentations of clinical data at major conferences. The company's net operating cash outflow was $28.7 million, largely driven by R&D expenses for the trial. Anteris is focused on its strategy to launch DurAVR® and has made significant strides in clinical trials and operational momentum across major markets.
Key Points
  • Anteris announced Q1 2026 financial results.
  • US$320 million raised for PARADIGM Trial.
  • DurAVR® THV System commercialization efforts.
  • U.S. enrolment for PARADIGM Trial began.
  • Net operating cash outflow of $28.7 million.
  • R&D expenses focused on trial and commercialization.
  • Clinical data presented at major conferences.
  • Global pivotal trial shows promising progress.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.